U.S. Software Stock News

In early March 2026, LifeMD, Inc. reported that it moved from a US$21.41 million annual net loss in 2024 to US$14.35 million net income in 2025, issued double‑digit revenue growth guidance for 2026, and highlighted expanding telehealth offerings including its oral Wegovy weight management launch with Novo Nordisk. This shift to profitability, combined with more than 322,000 active subscribers and growing GLP‑1 and women’s health programs, signals a business model that is scaling across...

If you are wondering whether NetApp's share price really reflects what the business is worth today, you are not alone. That is exactly what this article will unpack. NetApp shares last closed at US$98.66, with returns of 9.5% over 1 year, 71.3% over 3 years and 58.3% over 5 years. However, the stock has seen a 2.4% decline over 7 days, 6.8% over 30 days and 7.3% year to date. Recent company specific headlines have continued to keep investor attention on NetApp, helping frame how the market...

WM Technology (MAPS) closed out FY 2025 with Q4 revenue of about US$43.1 million and a basic EPS loss of roughly US$0.03, while trailing twelve month EPS stood at around US$0.02 on revenue of roughly US$174.7 million. Over recent periods the company has seen quarterly revenue range between about US$42.2 million and US$47.7 million, with EPS moving from a profit of roughly US$0.03 per share in late 2024 to small profits through most of 2025 before the latest quarterly loss. This has left...

If you are wondering whether Moelis shares offer good value at today's price, it helps to step back and look at what the current market is implying about the business. The stock last closed at US$51.75, after a 7.8% decline over the past week, a 25.1% decline over the past month, and a 27.3% decline year to date, while still showing a 51.6% return over 3 years and 23.6% over 5 years. These recent moves have kept Moelis on investors' radars, with market commentary often linking advisory firms...

Immunic, Inc. recently secured a key European patent for its lead asset vidofludimus calcium, aligning protection with existing U.S. coverage and potentially extending exclusivity into the 2040s for chronic inflammatory and autoimmune indications. This expanded intellectual property protection materially underpins the company’s core therapeutic franchise by lengthening its runway to develop and, if approved, commercialize its main clinical asset. Against this backdrop, we’ll explore how the...

Precision BioSciences (DTIL) closed out FY 2025 with Q4 revenue of US$34.2 million and Basic EPS of US$1.01, alongside earnings from discontinued operations of US$0.9 million and net income excluding extra items of US$19.2 million. Over recent quarters, the company has seen revenue range from US$0.6 million in Q4 2024 to US$34.2 million in Q4 2025. Over the same period, quarterly Basic EPS has moved from a loss of US$2.22 in Q4 2024 to a profit of US$1.01 in Q4 2025. This sets up an earnings...

TIC Solutions (NYSE:TIC) has appointed Ben Heraud as its new CEO, succeeding long-serving leader Tal Pizzey. The company has also launched a $200 million share repurchase program. These changes were recently announced and have not been widely discussed in prior coverage. TIC Solutions is making these moves at a time when its share price is $7.25, with the stock showing a 40.3% decline over the past year and a 26.7% decline year to date. The new leadership and buyback plan arrive against...

EverCommerce (EVCM) has wrapped up FY 2025 with fourth quarter revenue of US$151.2 million and basic EPS of US$0.03, alongside net income from ongoing operations of US$5.7 million. This caps a trailing twelve month period with revenue of US$588.9 million and EPS of US$0.10. Over recent quarters the company has seen revenue range from US$142.3 million to US$151.2 million, with quarterly EPS between US$0.01 and US$0.03. Over the same period, trailing twelve month net income from ongoing...

If you are wondering whether Fiverr International's current share price reflects its true worth, you are not alone. This article will walk you through what the numbers are actually saying about value. The stock has seen sizeable declines recently, with a 7.7% fall over the last week, a 27.6% decline over the last month, a 46.8% drop year to date, and a 59.2% decline over the past year. This extends a 68.5% and 95.3% fall across the last 3 and 5 years respectively. Recent attention on Fiverr...

If you are wondering whether RH's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are saying about the stock's value today. RH shares last closed at US$128.37, after returns of a 9.7% decline over 7 days, a 35.8% decline over 30 days, a 33.6% decline year to date, a 43.0% decline over 1 year, a 47.9% decline over 3 years and a 75.1% decline over 5 years. Recent coverage around RH has focused on how the company is positioned...

Donaldson Company (NYSE:DCI) has agreed to acquire Facet, a provider of filtration solutions for aerospace, defense, and power generation. The deal is intended to expand Donaldson's product lineup and deepen its presence in durable end markets tied to critical infrastructure and equipment. The acquisition adds exposure to customers that require highly technical filtration in mission critical applications. Donaldson Company focuses on filtration technologies across industrial, engine, and...

Wondering if Dell Technologies at around US$151.62 is still fairly priced, starting to look expensive, or offering value? This article is designed to help you frame that question clearly. The stock has seen strong momentum recently, with returns of 3.5% over 7 days, 22.1% over 30 days, 18.6% year to date, 61.4% over 1 year and 332.1% over 3 years. That naturally raises questions about what is already priced in. Recent coverage has focused on Dell as a key name in large scale computing and...

If you are wondering whether Blue Owl Capital's share price now reflects good value or just fresh risks, you are not alone. This article is here to unpack that question clearly. Over the short term the stock has seen sharp moves, with a 7 day return of an 11.5% decline, a 30 day return of a 30.6% decline and a year to date return of a 42.8% decline, while the 1 year return sits at a 51.8% decline compared to a 6.4% gain over 5 years and a 1.9% decline over 3 years. Recent headlines around...

Butler National (BUKS) has reported Q3 2026 revenue of US$26.9 million and basic EPS of US$0.10, set against trailing twelve month revenue of US$91.9 million and EPS of US$0.30 that came with 44.1% earnings growth and a 21.4% net margin over the past year. The company has seen quarterly revenue move from US$21.2 million in Q3 2025 to US$26.9 million in Q3 2026 and basic EPS from US$0.05 to US$0.10 across the same periods, with trailing net income reaching US$19.7 million, which positions the...

In recent weeks, Vital Farms reported weaker-than-expected quarterly earnings, prompting multiple law firms to launch securities investigations while the stock touched a new 52-week low and sector-wide pressures weighed on sentiment. Amid these legal probes and analyst concerns, Director Karl Khoury’s purchase of 5,000 additional shares stands out as a contrasting insider confidence signal. We’ll now examine how the earnings disappointment and resulting legal investigations might reshape...

In early March 2026, Tenaya Therapeutics reported a narrower full-year 2025 net loss of US$90.6 million and highlighted new preclinical data for TN-301 in Duchenne muscular dystrophy alongside a research collaboration with Alnylam Pharmaceuticals on up to 15 cardiovascular gene targets that could yield as much as US$1.13 billion in milestones. Together, these updates underscore how Tenaya is pairing emerging HDAC6 science in DMD and heart failure with a genetically guided partnership model...

Capricor Therapeutics (CAPR) has just posted its FY 2025 first half results with total revenue of US$0 million and a basic EPS loss of US$1.10, while trailing twelve month revenue sits at US$13.39 million with a basic EPS loss of US$1.66. Over recent periods, the company has reported revenue of US$8.88 million and US$13.39 million across the two halves of FY 2024, alongside basic EPS losses of US$0.66 and US$0.51. This provides context for how current margins remain under pressure. With...

Why Hess Midstream (HESM) is back on investor radars Hess Midstream (HESM) is drawing fresh attention after its board authorized a new buyback plan, and the partnership signed a repurchase agreement with JPMorgan to retire up to US$42 million of Class A shares. See our latest analysis for Hess Midstream. At a share price of US$38.99, Hess Midstream has recorded a 7.12% 1 month share price return and 11.94% 3 month share price return. Its 5 year total shareholder return of 166.77% contrasts...

Constellium (NYSE:CSTM) has announced a new share repurchase program of up to $300 million, authorized through the end of 2028. The new program replaces the previous buyback authorization. Constellium intends to use some repurchased shares to settle employee equity obligations, aiming to limit future dilution for shareholders. Constellium, trading at $24.61, has laid out a fresh $300 million buyback plan that directly addresses dilution, which many shareholders watch closely. The stock has...

Orchestra BioMed Holdings (OBIO) just posted a sharp step up in activity for FY 2025, with fourth quarter revenue at US$30.9 million and basic EPS of US$0.10, compared with a full year where trailing twelve month revenue sat at US$33.5 million and EPS on that basis was a loss of US$1.11. The company has seen revenue move from quarterly levels below US$1 million through most of the year to the current US$30.9 million print, while quarterly basic EPS shifted from losses between US$0.49 and...

If you have been wondering whether Universal Display's current share price reflects its true worth, you are not alone. This article aims to unpack that question clearly. The stock last closed at US$94.07, and returns of a 3.1% decline over 7 days, a 28.8% decline over 30 days, and a 22.8% decline year to date, as well as a 36.6% decline over 1 year, a 31.9% decline over 3 years, and a 57.2% decline over 5 years, may have reset expectations and risk perceptions for many investors. Recent news...

Northwest Bancshares (NasdaqGS:NWBI) President and CEO Louis J. Torchio recently acquired additional company shares, increasing his personal stake. The insider purchase took place around the time the bank reported strong fourth quarter financial results. The quarter featured earnings and revenue that were ahead of prior expectations, alongside the insider buying activity. Northwest Bancshares is a regional financial institution focused on community banking services, including deposits,...

USA Compression Partners (NYSE:USAC) has agreed to acquire J-W Power, expanding its contract compression fleet and specialty manufacturing capabilities. The deal is positioned around asset repricing opportunities and deeper participation in compression equipment manufacturing. Management is framing the combination as a way to serve rising demand tied to LNG infrastructure and power needs from AI focused data centers. Industry capacity remains tight, with longer lead times for new compression...

AC Immune (NasdaqGM:ACIU) just posted third quarter FY 2025 revenue of CHF 0.9 million and a basic EPS loss of CHF 0.16, with quarterly net income excluding extra items at a loss of CHF 15.9 million. Over recent periods the company has seen revenue move between CHF 0.7 million and CHF 25.5 million per quarter, while EPS has ranged from a loss of around CHF 0.23 per share to a modest profit of CHF 0.06 per share, which underscores how sensitive results can be to revenue timing. For investors,...